Neurology Clinical Trials Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The neurology clinical trials market is segmented by Phase (Phase I, Phase II, Phase III and Phase IV), Study Design (Interventional, Observational and Expanded Access), Indication (Epilepsy, Stroke, Alzheimer's Disease (AD), Parkinson's Disease (PD), and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Neurology Clinical Trials Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 4.35 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The neurology clinical trials market is expected to register a CAGR of 4.35% during the forecast period (2022-2027).

Covid-19 was an unprecedented event that has impacted nearly every aspect of businesses around the world. The ongoing clinical trials were delayed with disruptions to trial enrolment, data collection, and data analysis. A study titled "Impact of Covid-19 pandemic on clinical trials evaluating various neurology indications" published in April 2020 mentioned that a total of 81 trials with a definite neurology indication were identified as of April 2020. Indications related to pain and mental health are the most dominant, with 21% and 19% of the total indications. Also, the source mentioned that 11% of the trials evaluating various forms of addiction were impacted by the crisis.

However, the Covid-19 disease affects older people as well as people with underlying comorbidities. Neurological diseases are a common cause of mortality rate in an older population. People with dementia, for instance, majorly live with one or more chronic health conditions. As per Alzheimer's Disease International, more than 55 million people were living with dementia worldwide in 2020. And the risk of getting infected with Covid-19 was high for this target population. The memory impairment linked to dementia might interfere with the patient's ability to cooperate with preventive measures for COVID-19 like social distancing, mask-wearing, frequent hand sanitizing, and others. This led to much research and development. Hence, it is expected to have a positive impact on neurology clinical trials.

An increasing number of companies conducting clinical trials in neurology, the rising prevalence of various neurological diseases, and increasing research and development (R&D) investments and government funding towards neurological research are anticipated to drive the studied market growth.

According to Pan American Health Organization (PAHO), in 2019, regionwide neurological conditions accounted for 533,172 total deaths, among which 213,129 (40%) in men and 320,043 (60%) in women in North America.

In addition, a study entitled "Prevalence of dementia and its impact on mortality in patients with coronavirus disease 2019: A systematic review and meta-analysis" published in December 2020 showed when a total of 56,577 patients were taken for the study, the prevalence of dementia in this pooled analysis was 10%. Both adjusted and unadjusted effects for dementia associated with increased mortality were 72.9% and 93.7%, respectively. This burden of neurological diseases is expected to increase in the coming years, driving the demand for advanced therapies and treatments for neurological diseases. This is poised to drive the growth of the studied market.

However, stringent regulatory demand related to clinical trials and high failure rates, and increasing cost of clinical trials is anticipated to hinder the market growth over the forecast period.

Scope of the Report

As per the scope of the report, neurology clinical trials are experiments that are conducted under clinical research and follow a regulated protocol. These experiments are primarily performed to obtain data regarding the safety and efficacy of newly developed drugs in neurology for various indications. Neurology clinical trial data is mandatory for drug approval and for it to be introduced in the market.

The neurology clinical trials market is segmented by Phase (Phase I, Phase II, Phase III, and Phase IV), Study Design (Interventional, Observational, and Expanded Access), Indication (Epilepsy, Stroke, Alzheimer's Disease (AD), Parkinson's Disease (PD), and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Phase
Phase I
Phase II
Phase III
Phase IV
By Study Design
Expanded Access
By Indication
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Alzheimer’s Disease by Indication is Expected to Grow Over the Forecast Period

Alzheimer's Disease or AD is expected to boost the demand for neurology clinical trials and will grow at a stable growth rate in the forecast period.

Alzheimer's disease is one of the major problems in neuroscience, and it is majorly thought to be caused by an abnormal build-up of proteins inside and around brain cells. But it is still unknown what triggers Alzheimer's Disease (AD). The primary symptoms are problems with vision or language, while with the disease, different areas of the brain are affected, primarily those associated with memory.

According to National Health Service (NHS), although the factors causing this disease are unknown, there are several factors that are known that increase the risk of getting this disease. Such as age, family history, people living with Down's syndrome, Head injuries, and cardiovascular diseases are more prone to be affected by this disease.

The Alzheimer's Association 2021 report shows that the United States Food and Drug Administration (US FDA) has approved five drugs for the treatment of Alzheimer's, namely rivastigmine, galantamine, donepezil, memantine, and memantine combined with donepezil.

Additionally, in the article published by Alzheimer's Association titled "Alzheimer's disease drug development pipeline: 2021", there were 121 agents in clinical trials for the treatment of Alzheimer's disease. Twenty‐nine agents are in 36 Phase 3 trials, 65 agents are in 73 Phase 2 trials, and 27 agents are in 27 Phase 1 trials. Twelve agents in trials target cognitive enhancement, and 12 are intended to treat neuropsychiatric and behavioral symptoms. There were 97 agents in disease modification trials as of February 2020.

Owing to the increasing number of clinical trials and drug approvals, the Alzheimer's Disease segment by indication is expected to grow over the forecast period. Hence, driving the growth of the studied market.

Neurology Clinical Trials Market Research

North America is Expected to Dominate the Market in the Forecast Period

Factors such as high treatment awareness among the target population across the country, healthcare infrastructure, better reimbursement policies, and increasing business partnerships of pharmaceutical companies with contract research organizations are driving the growth of the United States neurology clinical trials market.

North America currently dominates the market for clinical trials for diagnostics and therapeutics, and it is expected to continue its stronghold for a few more years. The United States is anticipated to hold the largest share of the market.

According to a report published in March 2021, Alzheimer's Disease Facts and Figures, by 2050, this number is projected to rise to nearly 13 million. Additionally, the Centre for Disease Control and Prevention (CDC) data updated in April 2022 that every 40 seconds, someone in the United States has a stroke, and every 3.5 minutes, someone dies of a stroke. This burden of neurological disorders such as Alzheimer's Disease, stroke, and others is expected to drive the demand for new therapeutics in the market. Hence it is poised to drive the growth of the studied market.

In addition, as per CDC, stroke is a leading cause of serious long-term disability and reduces mobility in more than half of stroke survivors of age 65 and older in the United States. The geriatric population is one of the key factors responsible for the market growth in this country, as the older population is at a higher risk of acquiring this disease. The United States Census Bureau data, in 2019, about 54 million Americans were aged 65 years and above.

Therefore, owing to the aforementioned factors, the North American region is expected to witness strong growth over the forecast period driving the growth of the neurology clinical trials market.

Neurology Clinical Trials Market Analysis

Competitive Landscape

In the current scenario, the number of product launches, collaborations, and other strategies by the market players is increasing, and it's fueling the global neurology clinical trial market. The market is competitive in nature globally and fragmented due to the presence of several major players in the market. Supernus Pharmaceuticals, Inc. (Adamas Pharmaceuticals), AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd., Eli Lilly and Company, Aurora Health Care, AbbVie Inc., Zydus Group, Athira Pharma, Inc., Annovis Bio, Biogen, GlaxoSmithKline plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Sanofi are some of the major players among others.

Recent Developments

  • In March 2022, AbbVie announced plans to present 30 abstracts demonstrating its breadth of Neuroscience Portfolio and Pipeline, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia at the at American Academy of Neurology (AAN) 2022 Annual Meeting.
  • In December 2021, Zydus Cadila received approval to commence Phase II clinical study of its upcoming product with patients suffering from Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing number of companies Conducting Clinical Trials in Neurology

      2. 4.2.2 Rising Prevalence of Various Neurological Diseases

      3. 4.2.3 Increasing R&D Investments and Government Funding Towards Neurological Research

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Demand, High Failure Rates and Increasing Cost of Clinical Trials

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Phase

      1. 5.1.1 Phase I

      2. 5.1.2 Phase II

      3. 5.1.3 Phase III

      4. 5.1.4 Phase IV

    2. 5.2 By Study Design

      1. 5.2.1 Interventional

      2. 5.2.2 Observational

      3. 5.2.3 Expanded Access

    3. 5.3 By Indication

      1. 5.3.1 Epilepsy

      2. 5.3.2 Stroke

      3. 5.3.3 Alzheimer's Disease (AD)

      4. 5.3.4 Parkinson's Disease (PD)

      5. 5.3.5 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Supernus Pharmaceuticals, Inc. (Adamas Pharmaceuticals)

      2. 6.1.2 AstraZeneca

      3. 6.1.3 Novartis AG

      4. 6.1.4 Eisai Co., Ltd.

      5. 6.1.5 Eli Lilly and Company

      6. 6.1.6 Aurora Health Care

      7. 6.1.7 AbbVie Inc.

      8. 6.1.8 Zydus Group

      9. 6.1.9 Athira Pharma, Inc.

      10. 6.1.10 Annovis Bio

      11. 6.1.11 Biogen

      12. 6.1.12 GlaxoSmithKline plc

      13. 6.1.13 Merck & Co., Inc.

      14. 6.1.14 Teva Pharmaceutical Industries Ltd.

      15. 6.1.15 Sanofi

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Neurology Clinical Trials Market market is studied from 2019 - 2027.

The Global Neurology Clinical Trials Market is growing at a CAGR of 4.35% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

AbbVie Inc., Biogen, Merck & Co., Inc., Novartis AG, Sanofi are the major companies operating in Global Neurology Clinical Trials Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!